Categories: HumanITLifePlatformScienceBioTechCauseDevelopmentGrowthHealthTech
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
Location: United States, Massachusetts, Cambridge
Investors 2
Funding Rounds 2
Date | Series | Amount | Investors |
01.04.2021 | Series C | $126M | - |
31.07.2020 | - | $85M | - |
Mentions in press and media 14
Date | Title | Description | Source |
06.03.2024 | Omega Therapeutics Announces Two Poster Presentations at the... | - | globenewsw... |
10.09.2021 | Omega Therapeutics Reports Second Quarter 2021 Financial Res... | | prnewswire... |
29.07.2021 | Omega Therapeutics Announces Pricing of Initial Public Offer... | | prnewswire... |
23.06.2021 | Omega Therapeutics Expands Board of Directors with Appointme... | | prnewswire... |
31.03.2021 | Omega Therapeutics secures $126M to treat cancer and other d... | Omega Therapeutics has raised a $126 million Series C from investors including Flagship Pioneering, ... | pitchbook.... |
30.03.2021 | Biotech Startup Omega Therapeutics Grabs $126 Million | Omega Therapeutics Inc. has raised $126 million in venture financing to treat diseases by controllin... | wsj.com/ar... |
30.03.2021 | Omega Therapeutics, Inc. announced that it has received $126... | Omega Therapeutics, Inc. announced that it has received $126 million in series C round of funding on... | marketscre... |
30.03.2021 | Omega Therapeutics to Advance Pipeline and Platform Developm... | | prnewswire... |
13.01.2021 | Omega Therapeutics Announces the Industry's First Programmab... | | prnewswire... |
31.07.2020 | Omega Therapeutics snags $85M for genomic medicine | Massachusetts-based Omega Therapeutics has raised $85 million in new financing. Founded in 2017, the... | pitchbook.... |
30.07.2020 | Omega Therapeutics Lands $85M in Financing |
CAMBRIDGE, MA, Omega Therapeutics announced the completion of an $85 million financing.
>> ... | vcnewsdail... |
29.07.2020 | 'Genome-tuning' biotech Omega Therapeutics snags $85M as it ... | Less than a year after launch, Omega Therapeutics is getting an $85 million (PDF) cash boost. It wil... | fiercebiot... |
29.07.2020 | Omega Therapeutics Completes $85M in Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Omega Therapeutics, a company pioneering a new category of genomi... | citybizlis... |
29.07.2020 | 'Genome-tuning' biotech Omega Therapeutics snags $85M as it ... | Less than a year after launch, Omega Therapeutics is getting an $85 million (PDF) cash boost. It wil... | fiercebiot... |
Show more
Reviews 0